Samuvel Devadoss J, Jayanthi Lankupalle D, Bhat Narayan R, Ramamoorthy Sammanda
Department of Physiology and Neuroscience, Medical University of South Carolina, Charleston, South Carolina 29425, USA.
J Neurosci. 2005 Jan 5;25(1):29-41. doi: 10.1523/JNEUROSCI.3754-04.2005.
The serotonin transporter (SERT) is regulated by various signaling mechanisms that may operate to maintain appropriate levels of synaptic serotonin (5-HT). We demonstrate that one of the mitogen-activated protein kinases (MAPKs), p38 MAPK, regulates SERT. Treatment of rat midbrain synaptosomes with p38 MAPK-specific inhibitors, PD169316 [4-(4-fluorophenyl)-2-(4-nitrophenyl)-5-(4-pyridyl)-1H-imidazole] or SB203580 [4-(4-fluorophenyl)-2-(4-methylsulfinylphenyl)-5-(4-pyridyl)-1H-imidazole], reduced 5-HT uptake. An additive SERT inhibition by PD169316 and beta-phorbol 12-myristate 13-acetate (beta-PMA) indicated the involvement of a protein kinase C (PKC)-independent MAPK pathway. Kinetic studies indicated a significant decrease in the transport capacity (V(max)) after PD169316 treatment of synaptosomes. Biotinylation studies showed reduced SERT proteins in the plasma membrane of synaptosomes after p38 MAPK inhibition and PKC activation. Phosphorylation studies using synaptosomes revealed decreased SERT phosphorylation by PD169316 but increased phosphorylation by beta-PMA. d-Amphetamine enhanced SERT basal phosphorylation and PD169316 blocked this effect. SERT interaction with protein phosphatase 2A catalytic subunit and syntaxin 1A decreased after PD169316 or beta-PMA treatment of synaptosomes. In synaptosomes, PKC activation but not p38 MAPK inhibition resulted in SERT redistribution from cholesterolrich lipid raft fractions to nonlipid raft fractions. The presence of phospho-p38 MAPK in synaptosomes and human embryonic kidney 293 (HEK-293) cells suggested the presence of constitutively active p38 MAPK in these preparations. Cotransfection of HEK-293 cells with SERT and a constitutively active form of MAP kinase kinase 3b(E) [MKK3b(E)] increased 5-HT transport, and RNA interference targeted to p38 MAPK inhibited 5-HT uptake, confirming the involvement of active p38 MAPK in SERT expression. Although PD169316 inhibited SERT insertion to the plasma membrane, beta-PMA increased SERT internalization in HEK-293 cells. Together, these results indicate a distinct role of p38 MAPK in SERT regulation.
血清素转运体(SERT)受多种信号传导机制调控,这些机制可能参与维持突触中血清素(5 - HT)的适当水平。我们证明,丝裂原活化蛋白激酶(MAPK)之一的p38 MAPK对SERT具有调控作用。用p38 MAPK特异性抑制剂PD169316 [4 - (4 - 氟苯基) - 2 - (4 - 硝基苯基) - 5 - (4 - 吡啶基) - 1H - 咪唑] 或SB203580 [4 - (4 - 氟苯基) - 2 - (4 - 甲亚磺酰基苯基) - 5 - (4 - 吡啶基) - 1H - 咪唑] 处理大鼠中脑突触体,可降低5 - HT摄取。PD169316与β - 佛波醇12 - 肉豆蔻酸酯13 - 乙酸酯(β - PMA)对SERT的抑制作用具有相加性,表明存在一条不依赖蛋白激酶C(PKC)的MAPK途径。动力学研究表明,用PD169316处理突触体后,转运能力(V(max))显著降低。生物素化研究显示,抑制p38 MAPK并激活PKC后,突触体细胞膜中的SERT蛋白减少。使用突触体进行的磷酸化研究表明,PD169316可降低SERT的磷酸化水平,而β - PMA则使其磷酸化水平升高。d - 苯丙胺可增强SERT的基础磷酸化水平,而PD169316可阻断这一作用。用PD169316或β - PMA处理突触体后,SERT与蛋白磷酸酶2A催化亚基及 syntaxin 1A的相互作用减少。在突触体中,激活PKC而非抑制p38 MAPK可导致SERT从富含胆固醇的脂筏组分重新分布至非脂筏组分。突触体和人胚肾293(HEK - 293)细胞中存在磷酸化的p38 MAPK,表明这些制剂中存在组成型激活的p38 MAPK。将SERT与组成型激活形式的丝裂原活化蛋白激酶激酶3b(E)[MKK3b(E)] 共转染HEK - 293细胞可增加5 - HT转运,而针对p38 MAPK的RNA干扰可抑制5 - HT摄取,并证实活性p38 MAPK参与SERT表达。虽然PD169316可抑制SERT插入细胞膜,但β - PMA可增加HEK - 293细胞中SERT的内化。总之,这些结果表明p38 MAPK在SERT调控中具有独特作用。